secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theseus Pharmaceuticals, Inc. (—)
CIK:        0001745020
Form:       8-K
Filed at:   2023-12-04T23:59:59+00:00
Accession:  0001104659-23-123002
Event type: leadership
Sentiment:  negative
Materiality: 0.80
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Theseus Pharma terminates CEO and CMO; appoints CFO Dahms as President
----------------------------------------------------------------------

- CEO Timothy Clackson and CMO David Kerstein terminated without cause effective Dec 7, 2023 as part of workforce reduction.
- Clackson receives $0.9M severance plus 18-month equity vesting; Kerstein receives $0.6M plus 12-month equity vesting.
- CFO Bradford Dahms appointed President and director; salary increased to $500K; eligible for retention bonus of 1.5x salary.
- Dahms retention bonus paid in two installments; requires employment through earlier of strategic transaction or Feb 28, 2024.
- Both departing executives entered consulting agreements through Mar 31, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1745020/000110465923123002/0001104659-23-123002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1745020/000110465923123002/tm2332045d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-123002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer